Prior to joining DTL, Dr. Riggle developed, from idea to market, more than 10 different cannabis consumer products, facilitated and directed one of the first IRB approved clinical trials in the US involving a medical cannabis product, and reformulated several consumer products to remove potentially toxic and/or undesirable ingredients. He holds a Ph.D. in Analytical Chemistry from the University of Idaho in Moscow, ID, has been invited to speak at cannabis conferences across the globe, and has had multiple research presentations accepted by the International Cannabinoid Research Society.